Drug intelligence / Profile preview

EVM-201

Development stage: Preclinical
Lead developer: Enveric Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**EVM-201** is a second-generation psychedelic-inspired drug series being developed by Enveric Biosciences for mental health indications, particularly in the area of psychiatric disorders. The EVM-201 series includes new molecules in lead optimization aimed at providing improved characteristics compared to first-generation psychedelic therapies, such as oral psilocybin. Unlike the first-generation agent EVM-101, EVM-201 is described as a "pro-drug" series designed to address limitations of existing psychedelic agents, suggesting targeted, potentially improved pharmacological profiles for psychiatric or psychological distress and related indications[16][11].

Other names: EVM201 SeriesEVM-201 SeriesEVM 201 Series

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on EVM-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVM-201.

Explore the full profile